ADC Therapeutics elects Timothy Coughlin to board at 2025 AGM; all proposals pass

ADC Therapeutics SA

Timothy Coughlin elected to board; CPA, former Neurocrine CFO, appointed audit committee chair.
Binding votes: board max comp $2.3M, exec fixed $2.6M, variable $3.5M.
Amendment to 2019 Equity Incentive Plan approved to increase authorized shares.
Articles of association amended to raise conditional share capital for employee participation.
All 12 shareholder proposals, including director elections and say-on-pay, approved.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.